TNBC, aggressive and lacking key receptors, complicates treatment, impacting prognosis and requiring specialized approaches.

PR+ breast cancer responds well to hormone therapy, underscoring the need for molecular insight and targeted treatment ...

Pfizer and Arvinas' experimental breast cancer treatment failed to delay the progression of the disease in a broader group of ...

An experimental breast cancer treatment co-developed by Pfizer and Arvinas significantly improved the time some patients ...

Women with breast cancer who receive chemotherapy experienced a lasting decline in physical health, a new study found.

After a long period of annual declines, breast cancer mortality rates for women younger than 40 and older than 74 have ...

The first patients have been enrolled in the HEROES trial, exploring de-escalation of anti-HER2 therapy in metastatic HER2+ ...

A real-world study showed HER2DX guided treatment changes in approximately 48% of HER2-positive breast cancer cases.

Drs Ursula A. Matulonis and Katherine Fuh discuss the molecular classification and genetics of endometrial cancer as well as when to rebiopsy, research updates, and what's to come in the future.

Death rates from breast cancer will fall in 2025 in every age group in the EU and the UK apart from in EU patients aged 80 years and older. In these older patients, overall mortality rates from the ...

Breast cancer mortality rates have stopped declining for women over 74 and under 40, largely due to rising diagnoses of ...

Arvinas stock plummets 53% on mixed data from phase III metastatic breast cancer study on lead pipeline candidate, vepdegestrant.